taurursodiol
Selected indexed studies
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. (N Engl J Med, 2020) [PMID:32877582]
- Sodium Phenylbutyrate and Taurursodiol. (Am J Health Syst Pharm, 2023) [PMID:36645072]
- Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. (Ann Pharmacother, 2024) [PMID:37269231]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA. (2024) pubmed
- Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. (2022) pubmed
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. (2020) pubmed
- Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. (2024) pubmed
- Sodium Phenylbutyrate. (2006) pubmed
- Sodium Phenylbutyrate and Taurursodiol. (2023) pubmed
- An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. (2023) pubmed
- Addendum: Relyvrio withdrawn. (2024) pubmed
- NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. (2022) pubmed
- Endoplasmic reticulum stress disrupts signaling via altered processing of transmembrane receptors. (2025) pubmed